WA
VKTX icon

Wasatch Advisors’s Viking Therapeutics VKTX Stock Holding History

Wasatch Advisors’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.2M Sell
312,767
-391
-0.1% -$12.6K 0.08% 134
2026
Q1 		$10.2M Buy
313,158
+147,752
+89% +$4.75M 0.07% 126
2025
Q4 		$5.82M Buy
165,406
+36,939
+29% +$1.31M 0.03% 171
2025
Q3 		$3.38M Sell
128,467
-133,578
-51% -$3.99M 0.02% 204
2025
Q2 		$6.94M Buy
262,045
+4,597
+2% +$121K 0.04% 172
2025
Q1 		$6.22M Buy
257,448
+76,530
+42% +$2.42M 0.03% 175
2024
Q4 		$7.28M Sell
180,918
-46,802
-21% -$2.67M 0.04% 176
2024
Q3 		$14.4M Sell
227,720
-25,449
-10% -$1.49M 0.07% 138
2024
Q2 		$13.4M Sell
253,169
-2,367
-0.9% -$155K 0.07% 142
2024
Q1 		$21M Sell
255,536
-1,019,409
-80% -$45.4M 0.11% 132
2023
Q4 		$23.7M Buy
1,274,945
+311,681
+32% +$4.08M 0.13% 120
2023
Q3 		$10.7M Sell
963,264
-746,211
-44% -$10.7M 0.07% 143
2023
Q2 		$27.7M Buy
1,709,475
+4,031
+0.2% +$84.5K 0.17% 106
2023
Q1 		$28.4M Buy
+1,705,444
New +$17.6M 0.18% 106

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Wasatch Advisors's VKTX Position: Q2 2026 in Review

Wasatch Advisors reduced its Viking Therapeutics (VKTX) stake by 0.12% in Q2 2026, selling an estimated $12.6K and leaving 312,767 shares worth $12.2M. The position accounts for 0.08% of the portfolio, ranked #134.

Wasatch Advisors first reported a position in VKTX in Q1 2023 and has held it in 14 quarters since. The position peaked at $28.4M in Q1 2023. 436 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Wasatch Advisors held 312,767 shares of Viking Therapeutics worth $12.2M as of Q2 2026.
  • Wasatch Advisors sold 391 Viking Therapeutics shares in Q2 2026, an estimated $12.6K.
  • Viking Therapeutics made up 0.08% of Wasatch Advisors's portfolio in Q2 2026, its #134 holding.
  • Wasatch Advisors first reported a position in Viking Therapeutics in Q1 2023 and has held it in 14 quarters since.
  • Wasatch Advisors's Viking Therapeutics position peaked at $28.4M in Q1 2023.
  • 436 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Wasatch Advisors's 13F filing for Q2 2026, filed 10 Jul 2026.